Ferring present OA drug results at AAOS

18 May 2009

The US subsidiary of Ferring Pharmaceuticals presented the results of a six-month safety and efficacy study, demonstrating that Euflexxa (1%  sodium hyaluronate) was effective at decreasing the pain of knee  osteoarthritis compared to saline after 26 weeks, at the annual meeting  of the American Academy of Orthopedic Surgeons, held in Las Vegas,  Nevada.

The multicenter, 26-week, randomized, double-blind trial compared  Euflexxa and intra-articular buffered saline for level of pain following  a 50-Foot Walk Test, measured by 100 mm visual analog scale. The 586  patients with chronic idiopathic knee OA were randomized to treatment  with either product in a 1:1 ratio. Each patient received one weekly  injection for three weeks with nine follow-up visits over 26 weeks after  the first injection.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Companies featured in this story

More ones to watch >






Company Spotlight